Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of ICF004 in Healthy Chinese Participants

NCT07719218 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07719218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07719218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Inhaled Doses of ICF004 in Healthy Chinese Participants
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 30, 2026
Completion date
July 30, 2029
Enrollment
73 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, interstitial lung disease (ild)